The in vitro pharmacology of LY IGlar (LY2963016): A new insulin glargine product

Objective: Basal insulin analogs, with durations of action sufficient for coverage over the course of 24h, are important for the proper management of glycemic control in diabetic patients. LY2963016 (LY IGlar), an insulin analog has the same amino acid sequence as Lantus® (IGlar). The pharmacological properties of six independent lots of LY IGlar and IGlar were compared using a panel of in vitro biological assays to determine the pharmacological similarity of LY IGlar compared to IGlar. Methods: The affinity, Ki, for the human insulin receptor isoform A (hIR-A) and B (hIR-B) and human IGF-1 receptor (hIGF-1R) an…